- Home
- RARE
as of 12-22-2025 3:38pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 3.2B | IPO Year: | 2014 |
| Target Price: | $85.20 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.81 - $46.50 | Next Earning Date: | 11-04-2025 |
| Revenue: | $630,598,000 | Revenue Growth: | 20.63% |
| Revenue Growth (this year): | 19.09% | Revenue Growth (next year): | 20.62% |
AI-Powered RARE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
Chief Financial Officer
Avg Cost/Share
$36.38
Shares
3,081
Total Value
$112,086.78
Owned After
95,146
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$31.51
Shares
7,942
Total Value
$250,252.42
Owned After
95,146
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Dec 10, 2025 | Sell | $36.38 | 3,081 | $112,086.78 | 95,146 | |
| Horn Howard | RARE | Chief Financial Officer | Oct 13, 2025 | Sell | $31.51 | 7,942 | $250,252.42 | 95,146 |
Compare RARE vs Leading Stocks
See how RARE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.